Abstract CT250: A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancerOmar Saavedra, Nuria Kotecki, Fabricio Racca et al.|Cancer Research|2026Cited by 0
A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.Omar Saavedra, Nuria Kotecki, Fabricio Racca et al.|Journal of Clinical Oncology|2026Cited by 0
A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.Rafael Grochot, J O'Shaughnessy, P. Lorusso et al.|Journal of Clinical Oncology|2026Cited by 0